



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/695,155	10/27/2003	Marcus A. Horwitz	14376.218

ATTN: Louis C. Cullman
 STRADLING YOCCA CARLSON & RAUTH
 Suite 1600
 660 Newport Center Drive
 Newport Beach, CA 92660



CONFIRMATION NO. 6469

FORMALITIES LETTER



OC000000011847157

Date Mailed: 02/05/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

YIG
Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



EXPRESS MAIL NO: E4959882778 US

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/695,155	
	Filing Date	October 27, 2003	
	First Named Inventor	Marcus A. Horwitz et al.	
	Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	67	Attorney Docket Number	51326-00004 (14376-218)

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Check \$950.00, Notice to Comply Formalities Letter, Statement Under 37 CFR 1.821-1.825. See Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Louis C. Cullman, Registration No.: 39,645 Customer No.: 45,200 Preston Gates & Ellis	
Signature		
Date	7/6/04	

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Margaret M. Hasson
Signature	
Date	7/6/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


CERTIFICATE OF MAILING
I hereby certify that on July 6, 2004, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☐ 37 C.F.R. § 1.8(a)
with sufficient postage
as first class mail

☒ 37 C.F.R. § 1.10
as "Express Mail Post Office to Addressee"
Mailing Label No. 10/695,155

PATENT

Attorney Docket No.: 51326-00004 US (14376-218)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marcus A. Horwitz, et al.

Serial No.: 10/695,155

Filed: October 27, 2003

Title: ABUNDANT EXTRACELLULAR
PRODUCTS AND METHODS FOR THEIR
PRODUCTION AND USE

Conf. No.: 6469

Examiner: Unknown

Art Unit: Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**SUBMISSION OF SUBSTITUTE SEQUENCE LISTING, COMPUTER READABLE COPY
AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE LISTING**

Commissioner for Patents
Mail Stop Missing Parts
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the Notice to Comply with Requirements of Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated February 5, 2004, Applicants enclose herewith a copy of the Substitute Sequence Listing in computer readable (ASCII) form. A paper copy of the Substitute Sequence Listing in compliance with 37 C.F.R. §§ 1.821-1.825 for the nucleotide and/or amino acid sequences disclosed in the above-referenced application is also submitted herewith.


The computer readable (ASCII) form of the Substitute Sequence Listing submitted in this application is the same as the paper copy of the Substitute Sequence Listing to which it is indicated to relate.

All papers accompanying this submission introduce no new matter to the accompanying application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

July 6, 2004



Louis C. Cullman
Registration No. 39,645

Please contact the following for inquiries regarding the above submission:

Customer Number 45,200

Louis C. Cullman
Preston Gates Ellis LLP
1900 Main Street, Suite 600
Irvine, California 92614-7319
(949) 253-0900 Telephone
(949) 253-0902 Fax